Gilead and Kite Oncology to Showcase Axicabtagene Ciloleucel Advances at ASCO 2023
May 17, 2023 - FOSTER CITY, Calif. & SANTA MONICA, Calif. - Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present several key abstracts during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.
Kite Therapies Continue to Advance the Standard of Care in Leukemia and Lymphoma
A late-breaking oral presentation from the landmark Phase 3 ZUMA-7 study will highlight OS results for Yescarta® (axicabtagene ciloleucel) versus standard of care for initial treatment of adult patients with relapsed/refractory large B-cell lymphoma (LBCL) within 12 months of completion of first-line therapy.
Accepted Axicabtagene Ciloleucel abstracts at the 2023 ASCO Annual Meeting include (all times CDT):
|
B-cell Lymphomas |
|
|
Abstract #LBA107 (Oral Session) Monday, June 5 10:09 AM |
Primary Overall Survival Analysis of the Phase 3 Randomized ZUMA-7 Study of Axicabtagene Ciloleucel versus Standard-of-Care Therapy in Relapsed/Refractory Large B-Cell Lymphoma
|
|
Abstract #7547 Monday, June 5 8:00-11:00 AM |
Circulating Tumor DNA (ctDNA) by ClonoSEQ to Monitor Residual Disease after Axicabtagene Ciloleucel (Axi-Cel) in Large B-Cell Lymphoma (LBCL) |
|
Abstract #TPS7578 (TiP) Monday, June 5 8:00-11:00 AM |
ZUMA-23: A Global, Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel versus Standard of Care as First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma |
|
Follicular Lymphoma |
|
|
Abstract #7509 Monday, June 5 8:00-11:00 AM 1:15-2:45 PM (Poster Discussion) |
Real-World Early Outcomes of Axicabtagene Ciloleucel for Relapsed or Refractory (R/R) Follicular Lymphoma (FL) |
|
Abstract #TPS7579 (TiP) Monday, June 5 8:00-11:00 AM |
ZUMA-22: A Phase 3, Randomized Controlled Study of Axicabtagene Ciloleucel (Axi-Cel) versus Standard-Of-Care Therapy in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL) |